<DOC>
	<DOCNO>NCT00082394</DOCNO>
	<brief_summary>The aim study ass whether TRIZIVIR , administer twice-daily safe , tolerable efficacious combination drug COMBIVIR administer twice-daily atazanavir administer daily . Over course 48 week , various parameter measure safety , tolerability efficacy investigational drug measure compare .</brief_summary>
	<brief_title>A Study Comparing The Safety , Tolerability Efficacy Trizivir VS Combivir &amp; Atazanavir In Subjects With HIV</brief_title>
	<detailed_description>A Phase IV Randomized , Multicenter , Open-Label Study Compare Safety , Tolerability Efficacy Trizivir ( abacavir 300mg , lamivudine 150mg , zidovudine 300mg ) BID v Combivir ( lamivudine 150mg zidovudine 300mg ) BID plus atazanavir 400mg QD Antiretroviral Naive HIV-1 Infected Subjects 48 Weeks</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Inclusion criterion : Adults document HIV1 infection . Past use HIV drug must less 15 day . Plasma HIV1 RNA 500 20,000 copies/mL . CD4+ cell count great 100 cells/mm3 . Willing/able provide write informed consent . Exclusion criterion : Have AIDS screening . Pregnant breastfeeding . Underlying medical condition consider significant protocol . Participating investigational drug trial . In opinion investigator , would unable complete 48 week dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>TRIZIVIR</keyword>
	<keyword>COMBIVIR</keyword>
	<keyword>atazanavir</keyword>
	<keyword>HIV</keyword>
	<keyword>drug efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
</DOC>